AstraZeneca will conduct further development of AZD3480 for attention deficit/hyperactivity disorder (ADHD) and also plans to continue development of AZD1446 (TC-6683) for Alzheimer’s disease.
The company will press forward on research into the ADHD drug by initiating Phase IIb studies and has agreed to make a $10m milestone payment to Targacept to continue researching the drug.
Targacept is a biopharmaceutical company that designs, discovers and develops drugs for nervous system diseases and disorders.
AZD1446 for Alzheimer’s disease is currently in Phase I, and was discovered in the ongoing AstraZeneca-Targacept research collaboration.
The company has prioritised the development of AZD1446 over further development of AZD3480. AZD3480 and AZD1446 are selective alpha4beta2 NNR agonists.